USANA Health Sciences Stock Plummets After Severe Earnings Miss, Drastic Guidance Cut

Shares of USANA Health Sciences (NYSE: USNA) plunged in morning trading after the company released a deeply disappointing second-quarter earnings report and drastically lowered its financial outlook for the full year.

Disappointing Quarterly Results

For the quarter ending July 4, 2026, USANA reported an adjusted loss of $0.07 per share, a stark contrast to the consensus analyst estimate of a $0.43 profit, according to Investing.com. Quarterly revenue of $223 million also fell short of the anticipated $235 million and marked a 5.4% decline from the prior-year period.

The company's results were further impacted by a preliminary non-cash impairment charge of $29.1 million related to goodwill and intangibles. This charge drove the GAAP net loss to $(21.4) million for the quarter.

Guidance Slashed, Customer Metrics Weaken

The most significant factor driving the sell-off was a severe cut to the company's full-year 2026 guidance, which management detailed in its report and subsequent earnings call.

Ad

• Full-Year EPS Forecast: Lowered to $0.76, far below the analyst consensus of $2.12.
• Full-Year Revenue Forecast: Set at $910 million, missing the Street's model of $945.1 million.

Underlying these revisions are worsening customer metrics. The company reported that its Core Nutritional Active Customers declined to 384,000 from 418,000 year-over-year, adding to investor concerns about its demand trajectory.

Market Reaction and Context

The market's reaction was swift, with USANA's stock falling 26.1% and hitting a new 52-week low of $16.51 intraday. The decline erased the stock's gains from the previous three months.

The sell-off was entirely company-specific, as major indices like the S&P 500 and Nasdaq traded higher on the day. The convergence of a significant earnings miss, a large impairment charge, a dramatic guidance reduction, and weakening customer engagement created a perfect storm for the stock.